Abstract
A large number of HIV-infected patients in sub-Saharan Africa pay out-of-pocket for HAART. This analysis from Botswana indicates that higher median out-of-pocket regimen costs to patients for the initial 30 days of HAART are associated with failure to achieve a viral load< 400 copies/ml [US$32; interquartile range (IQR), 20-84 compared with US$22; (IQR, 17-36), P = 0.001]. HAART costs should be minimized as scale-up efforts in sub-Saharan Africa progress.
Original language | English (US) |
---|---|
Pages (from-to) | 1333-1336 |
Number of pages | 4 |
Journal | AIDS |
Volume | 20 |
Issue number | 9 |
DOIs | |
State | Published - Jun 2006 |
Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology
- Infectious Diseases